Brain Therapies Leads Medtronic’s Growth In First Quarter Of Fiscal 2020
Executive Summary
The medtech giant reported revenue of $7.5bn in the quarter that ended on 26 July, up 3.5% year-over-year basis, led by 12.5% growth in revenues from emerging markets. Medtronic’s fastest-growing business is its brain therapies unit, which reported 11.4% growth in the quarter.
You may also be interested in...
Medtronic Launches Platform To Gather Ideas To Improve Stroke Treatment
The Medtronic Neurovascular Co-Lab Platform is an “always on” online portal that will help Medtronic identify and work with developers of new technologies to prevent and treat strokes, a major cause of death and disability that is rarely treated effectively.
Medtronic Brain Imaging Software Recalled After 11 Injuries
The Minnesota-based medtech giant has had to recall software used on its StealthStation platforms used to help surgeons navigate a patient’s brain during surgery. Minor movements by the patient have been found to give false imaging that could endanger the patient’s life.
Medtronic Adds Stimgenics’ Novel Pain Therapy To Intellis Spinal Cord Stimulator
Medtronic acquired Stimgenics, an Illinois company it previously helped to fund, for an undisclosed sum. The company plans to add Stimgenics’ differential target multiplexed spinal cord stimulation waveform to its Intellis spinal cord stimulation system for the treatment of chronic pain.